All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2018-01-17T21:20:56.000Z

Daratumumab approved for use in England and Wales

Jan 17, 2018
Share:

Bookmark this article

On 17 January 2018, it was announced that daratumumab will now be available in the form of a monotherapy on the NHS, for the treatment of patients with Multiple Myeloma (MM) in England and Wales. This approval was granted by the National Institute of Clinical Excellence (NICE) and follows the decision granted by the Scottish Medicines Consortium (SMC) in October – see previous MM Hub article.

The therapy has been made available through the Cancer Drugs Fund (CDF), which provides faster access to the most promising cancer treatments, and will now allow access to MM patients that have received three prior lines of therapy that included a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) and have experienced disease progression during their last therapy. Access to such a novel therapy that has shown far-reaching benefits will be extremely welcome news for MM patients in England and Wales, although the limited indication as only a fourth line treatment is not quite what was hoped for and patient groups will certainly campaign for its extended use.

More about...

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox